Ziopharm Oncology (ZIOP) executives are pitching a turnaround strategy, claiming that recently enacted changes are freeing the struggling biotech to finally make good on past promises to develop new cancer immunotherapies.
So far, the “new” Ziopharm story seems to be resonating with investors. The company’s stock price bottomed out at just under $2 per share in late October. Since then, the stock is up 75 percent. Is this recent investor optimism in Ziopharm justified? Let’s take a closer look.
About the Author Reprints
